August 10, 2021 7:56am

Very lean pickings in Monday’s aftermarket – a forewarning?

News: bluebird bio (BLUE) dropped 27.45% on Monday, after the FDA paused its cerebral adrenoleukodystrophy trial for safety issues emerged and the suspension of its EU commercial operations.

Pre-open indications: 1 BUY; 1 SELLs: 3 SELLs into Strength; 1 Maintain SELL (read more)

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

There is no breadline for fact and numbers-based share pricing intelligence!

 


Dow futures are DOWN -0.03% (- 11 points), S&P futures are UP +0.01% (+0.50 point) and NASDAQ futures are UP +0.11% (+17 points)

 

U.S. stock futures were mixed and barely moving forward early Tuesday,

European stocks edged higher, cautiously,

Asia-Pacific stocks were mostly higher

 

Henry’omics:

Up, down, round and round – another day of trip, fall, kneel and stand upright as possible

Yesterday, Monday, the Dow fell 106.66 points to 35,101.85, or 0.3%, the S&P 500 traded down 0.1% at 4,432.35 and the Nasdaq rose 0.16% to 14,860.18.

Worries about the impact of Covid on global growth continued to weigh on investor sentiment, with countries grappling with the spread of the highly transmissible delta variant of the virus. <CNBC>

 

Monday’s evening’s recap: “as good as gets in these markets as sentiment wains” … https://www.regmedinvestors.com/articles/12040

  • The Nasdaq closed UP +24.42 points (+0.16%);
  • The IBB closed up +2.38% and XBI closed up +0.19%;
  • Sector volume was LOW with 8 of the 18-upside having higher than the 3-month average volume with very LOW volume of 1 of 15-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.57 points or +3.53% at 16.72;
  • Monday’s percentage (%) of the 18-upside were +0.32% (FATE) to +6.04% (VYGR) while the 15-downside ranges from -0.53% (AGTC) to -27.45% (BLUE);

Q3/21:

  • August: 4 positive and 2 negative close
  • July: 6 positives, 1 holiday and 15 negative closes

Q2/21:

  • June: 15 positive and 8 negative closes
  • May:  8 positive, 12 negative closes and 1 holiday
  • April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

Net Income:

  • CRISPR Therapeutics (CRSP);
  • uniQure NV (QURE);

Net losses:

  • Ultragenyx Pharmaceuticals (RARE);
  • Verastem (VSTM)
  • Alnylam Pharmaceuticals (ALNY);
  • Sage Therapeutics (SAGE);
  • Global Blood Therapeutics (GBT)
  • MiMedx (MDXG)
  • Ionis Pharmaceuticals (IONS);
  • Editas Medicine (EDIT);
  • Vericel (VCEL);
  • Brainstorm Cell Therapeutics (BCLI);
  • Intellia Therapeutics (NTLA);
  • Caladrius Biosciences (CLBS);
  • Sangamo Therapeutics (SGMO);
  • Adverum Biotechnologies (ADVM);
  • Cellectis SA (CLLS);
  • bluebird bio (BLUE);
  • Voyager therapeutics (VYGR);
  • Athersys (ATHX);
  • Regenxbio (RGNX);
  • Precigen (PGEN);

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped”?

Biostage (BSTG) closed down -$0.05 with 1060 shares traded after Friday’s +$0.05 on Friday with 709 shares traded after Thursday with 5 shares traded, Wednesday with 50 shares traded, Tuesday’s flat with 616 shares traded following last Monday’s -$0.05 to $1.60 with 571 shares traded.

Question#1: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND with NO clinical trial initiative … so WHERE and WHAT is the value proposition?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

Pre-open Indications:

SELL into Strength:

Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA)

 

Maintaining SELL:
Regenxbio (RGNX)

 

BUY:

Sage Therapeutics (SAGE)

 

The BOTTOM LINE: the recent bout of pricing inconsistency in the cell and gene therapy sector could be chalked up to LACK of any … impression in my 35 covered companies in this Q2 earnings season,

I was skittish over Friday and NERVOUS as Monday while Tuesday does not seem to be taking shape – re direction.  

The cell and gene therapy sector has experience dramatic upside move and downside putting a real edge on share pricing as earnings continued to guide sector sentiment … following last week’s twenty-one (21) releases to date.

Q2 earnings potential LPS (loss-per-share): coming “attractions”

  • BioLife Solutions (BLFS) – 8/12

Earnings’ Reports Outstanding:

  • Applied Genetic Technologies (AGTC), Bellicum Pharmaceuticals (BLCM), Biostage (BSTG), Homology medicine (FIXX), Mesoblast (MESO), Pluristem (PSTI) and Solid Biosciences (SLDB)

Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.

Risk is no doubt increasing as we head into the troublesome August and September months

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.